- Home
- / Tempest Therapeutics
Tempest Therapeutics
Stock Price
$1.1
2024-10-29
Market Capitalization
$27.7 M
2024-10-29
Tempest Therapeutics Summary
Company Summary
- Overview
- Tempest Therapeutics is a developer of targeted and immune-mediated cancer therapies. It provides small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.
- Type
- Public
- Status
- Active
- Founded
- 2011
- HQ
- Brisbane, CA, US | view all locations
- Website
- https://www.tempesttx.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Darrin Bomba, Vice President, Clinical Operations
Henry Johnson, Vice President, Chemistry, Vice President, Strategy and Finance
Geoff Nichol, Director
LocationsView all
1 location detected
Brisbane, CA HQ
United States
2000 Sierra Point Pkwy Ste. 400
Tempest Therapeutics Financials
Summary Financials
- Net income (Q1, 2026)
- ($27.7M)
- Cash (Q1, 2026)
- $1.8M
- EBIT (Q1, 2026)
- ($27.7M)
- Enterprise value
- $33.8M